Showing 351-360 of 7634 results for "".
Heart of the Matter: Effects of Psoriasis Treatment on CV Risks
https://practicaldermatology.com/topics/psoriasis/heart-of-the-matter-effects-of-psoriasis-treatment-on-cv-risks/18747/By Jashin Wu, MD and Seemal R. Desai, MDThere's growing evidence that treatment of psoriasis reduces the risk of CV events, but it's not clear whether this potential benefit should influence treatment decisions. Patient screening and counseling remain important, Dr. Wu says.Online Reputation Management: Take Charge
https://practicaldermatology.com/topics/practice-management/online-reputation-management-take-charge/18601/Why is reputation management important for healthcare practices? Medical practices have an expectation to protect. Negative opinions can be shred quickly and widely, swaying patient opinion. A majority of individuals (88%) trust online reviews as much as personal recommendations, according to researUnderstanding the Cosmetic Patient
https://practicaldermatology.com/topics/practice-management/understanding-the-cosmetic-patient/18785/Laurie Hurt, Marketing Director for Cosmetic Surgery and Dermatology at CareCredit, shares insights on the research and buying habits of cosmetic surgery patients gleaned from The Path to Purchase Study.Managing Comorbidites of Psoriasis
https://practicaldermatology.com/topics/psoriasis/managing-comorbidites-of-psoriasis/18808/Ron Prussick, MD explains why it's important for dermatologists to discuss the risks of comorbidities such as cardiovascular events, fatty liver disease, depression, and more with patients with psoriasis. While it needs to be determined if the treatments used to treat the outside effects of psoriasiCellfina Cleared, Finacea Foam Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-cellfina-cleared-finacea-foam-approved/18866/The FDA has cleared Cellfina (Ulthera Inc./Merz Aesthetics, Inc.) to treat cellulite, with results lasting for up to 2 years. Finacea Foam (azelaic acid, Bayer Dermatology) is approved for Rosacea, and Almirall invests in Suneva Medical, maker of Bellafill. Also in this edition, a look at the data oAdvocacy Groups and Physicians: The New Power Couple
https://practicaldermatology.com/topics/practice-management/advocacy-groups-and-physicians-the-new-power-couple/21191/Patient advocacy organizations partnering with dermatology physician-scientists offer an exciting new model for optimized patient care.Recently Passed Law Clears Way for New Sunscreen Ingredients
https://practicaldermatology.com/topics/skin-cancer-photoprotection/recently-passed-law-clears-way-for-new-sunscreen-ingredients/21232/By forcing the FDA to clear its backlog of sunscreen ingredients pending review, The Sunscreen Innovation Act is a major win for UV protection efforts.Preserve the Core; Live Your Aesthetic
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/preserve-the-core-live-your-aesthetic/19083/Heidi Waldorf, MD, FAAD and Steven Dayan, MD, FACS, Co-Chief Medical Editors of Modern Aesthetics®magazine, talk about the importance of staying true to your aesthetic and address the challenges of preserving the core specialties.Sunscreen Water Seems All Washed Up; Fake Cosmeceuticals Raise Concerns
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-sunscreen-water-seems-all-washed-up-fake-cosmeceuticals-raise-concerns/19119/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine we take a look at drinkable sunscreen and school bans on sunscreens, get an update on Vegas Cosmetic Surgery, and meet the new face of AMBI skincare. Plus, our DermFocus investigates the problem of counterfeit cosThe Hedgehog Pathway: Updates in Safety and Efficacy in Basal Cell Carcinoma Treatment
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-hedgehog-pathway-updates-in-safety-and-efficacy-in-basal-cell-carcinoma-treatment/21418/Recent findings may improve how physicians understand BCCs and, more specifically, how hedgehog inhibitors can be harnessed to treat them.